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cense. httpAbstract Primary liver cancer is the ﬁfth most common cancer worldwide and the third most com-
mon cause of cancer mortality. For patients with early resectable disease, surgical resection or trans-
plantation is considered a potentially curative modality for hepatocellular carcinoma (HCC); on the
other hand, for patients with unresectable or metastatic disease, treatment is essentially palliative
and prior to the approval of sorafenib, there was no globally approved systemic treatment for
patients presenting with unresectable or metastatic HCC. Sorafenib is the only systemic treatment
to demonstrate a statistically signiﬁcant but modest overall survival beneﬁt in a large phase III trial.
Thus, novel systemic approaches represent a high unmet medical need in advanced HCC. In this
review article, we will try to take a journey through the history of systemic therapeutic options
for HCC passing through the current standard options and exploring the potential new systemic
options for this disease.
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Primary liver cancer is the ﬁfth most common cancer world-
wide and the third most common cause of cancer mortality.
Globally, over 560,000 people develop liver cancer each year
and an almost equal number, 550,000, die of it. Liver cancer
burden, however, is not evenly distributed throughout the
world. Most HCC cases (>80%) occur in either sub-Saharan
Africa or in Eastern Asia. China alone accounts for more than
50% of the world’s cases (age-standardized incidence rate
(ASR) male: 35.2/100,000; female: 13.3/100,000) [1].
HCC is a complex disease associated with many risk factors
and cofactors. In most patients, HCC is preceded by cirrhosis
of the liver and, unsurprisingly, common causes of cirrhosis
have been identiﬁed as key risk factors for HCC. Of particular
importance is chronic infection with HBV or hepatitis C virus
(HCV). Indeed, it has been estimated that HBV is responsible
for 50–80% of HCC cases worldwide, whereas 10–25% of
cases are thought to be a result of HCV infection [2].
At the initial diagnosis, surgical resection or transplanta-
tion is considered a potentially curative modality for HCC; Pa-
tients with localized unresectable disease are usually treated
with some form of localized therapy. Local therapeutic modal-
ities include targeted chemotherapy through hepatic artery
combined with embolization, percutaneous ethanol ablation,
radioembolization, radiofrequency ablation, and cryosurgery
[3].
Prior to the approval of sorafenib, there was no globally
approved systemic treatment for patients presenting with unre-
sectable or advanced metastatic HCC. Sorafenib is the only
systemic treatment to demonstrate a statistically signiﬁcant
but modest overall survival beneﬁt in a large phase III ran-
domized, placebo-controlled trial (SHARP; sorafenib HCC
Assessment Randomized Protocol Trial) [4]. Thus, novel ap-
proaches for the treatment of unresectable advanced or meta-
static HCC represents a high unmet medical need. In this
review article, we will try to take a journey through the history
of systemic therapeutic options for HCC passing through the
current standard options and exploring the potential new
systemic options for this disease.
Research methodology
An updated summary of the preclinical and clinical experience
with various systemic therapies in HCC is presented in a chro-nological order. Data are based on abstracts from interna-
tional conferences and journal articles found in a Pub Med
search of literature published up to June 2013.Chemotherapy
Chemotherapeutic agents have been studied extensively in
hepatocellular carcinoma (HCC), with phase II trials yielding
response rates ranging from 10% to 20% but never demon-
strating an improvement in overall survival compared with
best supportive care. Doxorubicin is the most extensively
studied agent in advanced HCC, with response rates ranging
from 0% to 79% [15]. Other chemotherapy agents that have
been studied in HCC include docetaxel, paclitaxel, irinotecan,
capecitabine, tegafur-uracil (UFT) and gemcitabine; however,
none of these agents has demonstrated any survival advan-
tage [5–9].
Because of the lack of survival advantage with mono-
therapy for advanced HCC, combination regimens have been
studied in HCC. Again, the results of combination chemother-
apy regimens (gemictabine-based, taxane based or anthracy-
cline based) were disappointing with no demonstrated
survival beneﬁt [11–13]. Probably, the most interesting combi-
nation chemotherapy regimen is the PIAF regimen (cisplatin,
interferon alfa-2b, doxorubicin, and 5-ﬂuorouracil) which
demonstrated a response rate of 26% and a median survival
of approximately 9 months in a single-arm phase II trial [14].
These positive results led to the evaluation of PIAF in a large
randomized study versus doxorubicin [15]. However, the re-
sults of this study was again disappointing and did not meet
its primary endpoint, with median survivals of 8.6 months
for PIAF versus 6.8 months for doxorubicin (P= 0.83)
(Table 1).Molecular targets in hepatocellular carcinoma
With the lack of a standard of care, the urgent need to eval-
uate novel therapeutic options for patients with advanced
HCC became clear. These efforts began at the same period
that basic science researchers were delineating a better
proﬁle of the carcinogenesis of HCC and the relevant path-
ways involved. Potential targets of interest in HCC include
the epidermal growth factor receptors and the angiogenic
pathway [16].
T
a
b
le
1
S
el
ec
te
d
re
su
lt
s
o
f
cy
to
to
x
ic
ch
em
o
th
er
a
p
y
a
g
en
ts
u
se
d
in
H
C
C
tr
ea
tm
en
t.
S
tu
d
y
A
g
en
t
u
se
d
D
o
se
/c
y
cl
e
D
is
ea
se
co
n
tr
o
l
ra
te
(D
C
R
)
(C
R
+
P
R
+
S
D
)
M
ed
ia
n
O
S
M
o
st
co
m
m
o
n
to
x
ic
it
ie
s
A
b
d
el
-R
a
h
m
a
n
et
a
l.
[4
8
]
C
a
p
ec
it
a
b
in
e
1
0
0
0
m
g
/m
2
5
6
.8
%
5
.0
7
m
s
H
y
p
er
b
il
ir
u
b
in
em
ia
a
n
d
d
ia
rr
h
ea
H
eb
b
a
r
et
a
l.
[6
]
D
o
ce
ta
x
el
7
5
–
1
0
0
m
g
/m
2
5
5
%
N
/R
F
a
ti
g
u
e
a
n
d
n
eu
tr
o
p
en
ia
C
h
a
o
et
a
l.
[7
]
P
a
cl
it
a
x
el
1
7
5
m
g
/m
2
2
5
%
N
/R
N
eu
tr
o
p
en
ia
,
th
ro
m
b
o
cy
to
p
en
ia
,
in
fe
ct
io
n
a
n
d
a
ll
er
g
y
B
o
ig
e
et
a
l.
[8
]
Ir
in
o
te
ca
n
2
0
0
–
3
5
0
m
g
/m
2
(a
cc
o
rd
in
g
to
s.
b
il
ir
u
b
in
)
4
4
%
7
.4
m
s
N
eu
tr
o
p
en
ia
,a
n
em
ia
a
n
d
d
ia
rr
h
ea
P
a
n
d
e
et
a
l.
[1
1
]
G
em
ci
ta
b
in
e/
ci
sp
la
ti
n
co
m
b
in
a
ti
o
n
a
G
em
ci
ta
b
in
e
1
.2
g
m
/m
2
D
1
/D
8
a
C
is
p
a
lt
in
7
5
m
g
/m
2
D
1
7
5
%
7
.5
m
s
A
n
em
ia
.
th
ro
m
b
o
cy
to
p
en
ia
a
n
d
n
eu
tr
o
p
en
ia
Y
eo
et
a
l.
[1
5
]
P
IA
F
(c
is
p
la
ti
n
/i
n
te
rf
er
o
n
a
lf
a
/d
o
x
o
ru
b
ic
in
/5
F
U
)
a
C
is
p
a
lt
in
:2
0
m
g
/m
2
D
1
–
D
4
a
In
te
rf
er
o
n
a
lf
a
:
5
u
/m
2
D
1
–
D
4
a
D
o
x
o
ru
b
ic
in
4
0
m
g
/m
2
a
5
F
U
:
4
0
0
m
g
/m
2
D
1
–
D
4
6
0
%
8
.6
7
m
s
N
eu
tr
o
p
en
ia
,
th
ro
m
b
o
cy
to
p
en
ia
a
n
d
h
y
p
o
k
a
le
m
ia
a
N
/R
:
n
o
t
re
p
o
rt
ed
.
Systemic treatment for (HCC): from bench to bedside 167Epidermal growth factor receptor inhibitors
The importance of the epidermal growth factor receptors
(EGFR) pathway in hepatocellular carcinoma (HCC) is still
under investigation. Nonetheless, several EGFR tyrosine ki-
nase inhibitors have been studied in HCC. Erlotinib has been
studied alone and in combination in a number of phase II trials
both as ﬁrst line and after failure of sorafenib [17–19]; however
the response rate was modest both in monotherapy and in
combination.
Cetuximab, an anti-EGFR monoclonal antibody, was also
tested in advanced HCC, both as a single agent and in combi-
nation, however it did not demonstrate signiﬁcant antitumor
efﬁcacy worthy of further consideration in advanced HCC
[20–22].
Inhibitors of the proangiogenic pathway
Angiogenesis, which involves the vascular endothelial growth
factor (VEGF) family, is a critical component in the develop-
ment of hepatocellular carcinoma (HCC). In preclinical stud-
ies, VEGF has been found to augment the metastatic
potential of HCC tumors [23].
This metastatic potential is thought to be governed by the
overexpression of platelet-derived growth factor receptor-beta
(PDGFR-b) in HCC [29]. Sorafenib, a multityrosine kinase
inhibitor is the most extensively studied agent of this
category.Sorafenib preclinical pharmacology
Sorafenib, a multityrosine kinase inhibitor, targets angiogenic
VEGFR-1, -2, and -3; PDGFR-b; and tumorigenic RET, Flt-
3, and c-Kit receptors. In human hepatocellular tumor cell
lines, sorafenib potently inhibited cellular proliferations, Raf/
MEK/ERK signaling and induced apoptosis [39].
Clinical experience with sorafenib
Clinical results in Phase I studies of sorafenib as a single agent
were indicative of a therapeutic effect in HCC and led to the
design of a single phase II trial of sorafenib in 137 patients
with advanced-stage HCC yielding encouraging efﬁcacy and
tolerability results [40]. However, 33.6% of patients treated
had stable disease (P16 weeks) commensurate with an inde-
pendently reviewed, relatively improved median time to pro-
gression of 5.5 months. The median overall survival of the
study population was 9.2 months, comparing favorably with
historical controls.
The results of this study provided the basis for the random-
ized, placebo-controlled Phase III study in subjects with ad-
vanced HCC Child–Pugh class A. This large (602 subjects)
Phase III study was the ﬁrst international, randomized, dou-
ble-blind, placebo-controlled study to demonstrate a statisti-
cally signiﬁcant and clinically meaningful improvement in OS
in advanced HCC subjects treated with sorafenib over placebo.
Of the 299 sorafenib subjects valid for ITT analysis, the med-
ian OS was 10.7 months in the sorafenib group and 7.9 months
in the 303 subjects randomized to the placebo group. There-
fore, sorafenib had a statistically signiﬁcant effect on prolong-
ing overall survival [42].
Table 2 Selected results of targeted agents used in HCC treatment.
Study Agent Dose Disease
control
rate (%)
Median OS Most common toxicities
Santoro et al. [10] Trivantinib 360 mg twice daily 60 N/R Neutropenia and anemia
Philip et al. [19] Erlotinib 150 mg daily 59 13 ms Skin toxicity and diarrhea
Zhu et al. [20] Cetuximab 250 mg/m2 17 N/R Elevated AST, hypomagnesemia,
fever without neutropenia
Thomas et al. [28] Bevacizumab/erlotinib abevacizumab: 10 mg/kg every
14 days
aerlotinib:150 mg daily
62.5 13.5 ms Hemorrhage, wound infection,
thrombocytopenia and proteinuria
Faivre et al. [33] Sunitinib 50 mg/day for 4 weeks followed
by 2 weeks rest
37.5 N/R Thrombocytopenia, neutropenia and
hand foot skin reaction
Park et al. [34] Brivanib 800 mg once daily 48 10 ms Fatigue, hypertension and diarrhea
a N/R: not reported.
168 O. Abdel-RahmanAnother phase III randomised, double-blind, placebo-con-
trolled trial was conducted in patients in the Asia-Paciﬁc re-
gion with advanced hepatocellular carcinoma. Of these, 226
patients were randomly assigned to the sorafenib group
(n= 150) or to the placebo group (n= 76). Median overall
survival was 6.5 months in patients treated with sorafenib,
compared with 4.2 months in those who received placebo [43].
And so, taken together with data from the Sorafenib Hepa-
tocellular Carcinoma Assessment Randomised Protocol
(SHARP) trial, sorafenib seems to be an appropriate option
for the treatment of advanced hepatocellular carcinoma.
Sorafenib plus chemotherapy combination
In spite of improvement in terms of overall survival (OS) and
time to progression (TTP), in all studies where sorafenib was
compared to placebo, the sorafenib arm was not accompanied
by a signiﬁcant volumetric reduction, and this may explain the
lack of any symptomatic improvement (time to symptomatic
progression (TTSP) was almost identical between sorafenib
and placebo).
Reviewing the chemotherapy outcome, although there is no
convincing evidence in survival beneﬁt to patients with ad-
vanced HCC, however true shrinkage (reduction in tumor
size), has been consistently reported although the magnitude
of response is lacking consistency.
This indicates the need for coupling sorafenib to a chemo-
therapeutic agent but:
 For patients with hepatocellular carcinoma, the toxicity
proﬁle of any chemotherapeutic agent of choice to be added
to sorafenib should be taken into consideration
 The agent to be added to sorafenib should be effective in
terms of Tumor Shrinkage & with minimal toxicity regard-
ing: cardio-toxicity, HFSR, Diarrhea, Hepato-toxicity,
bone marrow suppression (although not relevant to the tox-
icity proﬁle of sorafenib, yet the HCC patients may have
HCV related thrombocytopenia and variable degree of
hypersplenism related pancytopenia), Circulatory Overload
(Hypertension).
Accordingly, a number of phase 2/3 studies have been
launched all over the world comparing ‘‘sorafenib plus’’ com-bination to sorafenib monotherapy; the ﬁrst to these studies is
the Nexavar-Tarceva Combination Therapy for First Line
Treatment of Patients Diagnosed with Hepatocellular Carci-
noma (SEARCH) (NCT00901901); initial results of the study
were published in a press release in the ESMO congress
2012, Vienna and unfortunately it was negative with no
improvement in overall survival or time to progression [41].
Our group in Egypt – the Egyptian Society of Liver Cancer
– one study testing the value of combining Sorafenib Plus
Tegafur-uracil (UFT) versus Sorafenib as First Line Systemic
Treatment for Patients With Advanced Stage HCC (ESLC 1
study) (NCT01539018), the study is still recruiting partici-
pants; another German group has launched a phase 2 study
testing the value of combining Sorafenib Plus Doxorubicin
versus Sorafenib Alone for the Treatment of Advanced Hepa-
tocellular Carcinoma (SORADOX study) (NCT01272557);
this study is also recruiting participants; a 3rd group from
the USA has launched a phase 2 study Combination of Temsi-
rolimus and Sorafenib in Advanced Hepatocellular Carci-
noma, the study is still recruiting participants (NCT01687673).
Other antiangiogenic therapies
Bevacizumab, an anti-VEGF monoclonal antibody, was also
tested in advanced HCC, both as a single agent and in combi-
nation; however, despite initial encouraging results, further
conﬁrmatory studies were disappointing [25–29].
Cediranib, potent inhibitor of vascular endothelial growth
factor signaling, has also been tested in a phase 2 study of ad-
vanced HCC, however, owing to toxicity, the drug was not
found to be an appropriate treatment in patients with unresec-
table or metastatic HCC [30].
Sunitinib, another multi kinase inhibitor, although it had
initial encouraging results both in the ﬁrst line and post sorafe-
nib settings [31–33], a phase 3 head to head comparison of sun-
itinib versus sorafenib showed discouraging results
(NCT00699374).
Brivanib, a selective dual inhibitor of ﬁbroblast growth fac-
tor and VEGF signaling, has demonstrated encouraging anti-
tumor activity in preclinical and phase 1 and 2 studies
(Table 2) [34]. However, despite positive signals seen with briv-
anib in the phase II study, the results of its phase III – reported
in an abstract form earlier in 2012 – was negative (in this phase
Figure 1 Current and future targeted therapeutics for hepatocellular carcinoma (VEGFR: vascular endothelial growth factor receptor,
PDGFR: platelet derived growth factor receptor, mTOR: mamilian target of rapamycin, EGFR: epidermal growth factor receptor)
Systemic treatment for (HCC): from bench to bedside 1693 study, brivanib did not signiﬁcantly improve OS in advanced
HCC patients who failed sorafenib) and further search for ac-
tive second line agents is ongoing [35].
Thalidomide is another anti-neoplastic agent with anti-
angiogenic and other mechanisms of action. Initial phase 1/2
data were encouraging with modest antitumor activity and tol-
erable side effects [36,37]; however, with the appearance of the
results of phase 3 sorafenib studies, interest in thalidomide has
faded away.
Linifanib is another potent and selective inhibitor of the
vascular endothelial growth factor (VEGF) and platelet-de-
rived growth factor (PDGF) receptor tyrosine kinase families.
In a phase II trial in patients with advanced HCC, Lin showed
clinical activity objective response rate [ORR] 10.5% in Child-
Pugh A patients [44]. So, it has been compared to sorafenib in
a phase 3 study which showed that linifanib and sorafenib re-
sulted in similar OS in advanced HCC. Predeﬁned superiority
and non-inferiority OS boundaries were not met for linifanib.
Secondary endpoints (TTP and ORR) favored linifanib while
safety results favored sorafenib[43].
mTOR inhibitors
Due to encouraging results in other solid tumors like kidney
cancer and breast cancer, interest in MTOR inhibitors for
HCC was stimulated recently, with a number of phase1/2 stud-
ies showing encouraging results [38]; however the issue of viral
reactivation is alarming for the majority of HCC patients with
underlying Hepatitis B or C infection.
C-Met inhibitors
A recent phase 2 study has provided hope for tivantinib (ARQ
197), a C-Met inhibitor, as a potential 2nd line candidate after
sorafenib failure particularly in Met-high HCC; Time to pro-
gression was longer for patients treated with tivantinib
(1.6 months) than placebo (1.4 months, p= 0.04). For patients
withMET-high tumours,median time to progressionwas longer
with tivantinib than for those on placebo (2.7 months for 22
MET-high patients on tivantinib versus 1.4 months for 15
MET-high patients on placebo; p= 0Æ03) (Table 2) [10]. This
study provides a proof of concept that personalized targeted
therapy is paving its way in the ﬁeld of HCC research.Immunotherapy for HCC
Another rapidly evolving and promising strategy is the use of
immunotherapeutic approaches to treat HCC; the most com-
monly implemented immunotherapeutic strategy was the use
of peptide vaccines. Based on the promising preclinical mice
data, a number of phase 1 and 2 clinical studies have been con-
ducted with initial encouraging results [45–47], however, data
are still not mature enough in this research area to draw ﬁrm
clinically oriented recommendations.
Conclusions
HCC is an active area for basic and clinical cancer research;
with a rapidly changing therapeutic landscape (Fig. 1). We be-
lieve that basic and applied multicentre HCC research should
be put as a priority for all the academic institutions in the Mid-
dle East to tackle this difﬁcult to treat aggressive disease in the
Middle East.
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